New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - quinapril hydrochloride 21.664mg equivalent to 20 mg quinapril base - tablet - 20 mg - active: quinapril hydrochloride 21.664mg equivalent to 20 mg quinapril base excipient: candelilla wax crospovidone gelatin heavy magnesium carbonate lactose monohydrate magnesium stearate opadry brown y-5-9020 opadry brown y-5-9020g

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril hydrochloride 10 mg - quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration ). in using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that quinapril does not have a similar risk (see warnings: neutropenia/agranulocytosis ). angioedema in black patients: black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials, ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride and hydrochlorothiazide tablets are contra

United States - English - NLM (National Library of Medicine)

apotex corp - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - hypertension quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril hydrochloride and hydrochlorothiazide. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education progr

United States - English - NLM (National Library of Medicine)

greenstone llc - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - quinapril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 20 mg - quinapril hydrochloride/hydrochlorothiazide tablets are indicated for the treatment of hypertension.  this fixed combination is not indicated for the initial therapy of hypertension (see dosage and administration ). in using quinapril hydrochloride/hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. available data are insufficient to show that quinapril does not have a similar risk (see warnings: neutropenia/agranulocytosis ). angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials, ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride/hydrochlorothiazidetablets are contraindicated

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; iron oxide yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; calcium sulfate dihydrate; magnesium carbonate hydrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - hypertension: quinapril hcl and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril hcl and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; magnesium stearate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; crospovidone; titanium dioxide; iron oxide yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - quinapril hydrochloride - oral tablet - 20mg